格隆汇2月20日丨华东医药(000963.SZ)于2023年2月15日14:30-16:00；2月16日11:00-11:40、14:00-15:00接受机构现场调研时表示，美琪健康已经积累了一批意向客户及订单，将为今年下半年正式投产后的发展打下良好基础。华仁科技以小核酸药物和诊断试剂用核苷原料为主要业务领域，随着全球疫情形势的放缓，诊断试剂类业务增速较之前将有所下降。但是小核酸药物用核苷原料领域仍然具有较大的潜力与拓展空间，华仁科技也有较为丰富的产品库，今后将加快该类业务产业化，并在公司国际化能力的助力下，持续拓展国际市场，今年争取比去年整体有较快的增速，不断增强公司工业微生物核苷类业务的市场竞争力。
Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.
